Clinical Trial Update: Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer [NA]

View source ↗

Summary

A completed clinical trial evaluating fragmentation of elastin as a biomarker of frailty and its impact on tumor progression in elderly patients with cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Snippet

Sponsor: CHU de Reims | Conditions: Cancer | NA | Status: COMPLETED